Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.

MLA

Autore, Francesco, et al. “Correspondence in Reference to the Previously Published Manuscript: Reduction of Cycles of Bendamustine plus Rituximab Therapy in the Cases with Good Response for Indolent B-Cell Lymphomas.” Hematological Oncology, vol. 41, no. 3, Aug. 2023, pp. 571–73. EBSCOhost, https://doi.org/10.1002/hon.2989.

APA

Autore, F., Fresa, A., Innocenti, I., Principe, M. I. D., Maglione, R., Stefanizzi, C., Pelliccia, S., Romeo, A., Cimino, G., Papa, E., Padua, L. D., Andriani, A., Mengarelli, A., Tafuri, A., Ditto, C., Mauro, F. R., Del Poeta, G., & Laurenti, L. (2023). Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas. Hematological Oncology, 41(3), 571–573. https://doi.org/10.1002/hon.2989

Chicago

Autore, Francesco, Alberto Fresa, Idanna Innocenti, Maria Ilaria Del Principe, Raffaele Maglione, Caterina Stefanizzi, Sabrina Pelliccia, et al. 2023. “Correspondence in Reference to the Previously Published Manuscript: Reduction of Cycles of Bendamustine plus Rituximab Therapy in the Cases with Good Response for Indolent B-Cell Lymphomas.” Hematological Oncology 41 (3): 571–73. doi:10.1002/hon.2989.